Archived Facts

COPENHAGEN (Reuters) – U.S. health regulators have postponed a decision on Danish drugmaker Novo Nordisk’s insulin degludec to allow for a review by outside experts, delaying further the potential blockbuster’s route to market.

Popular Posts:

Related Posts:

Leave a Reply